The risk of hemorrhagic conversion after stroke ( HR : 1.19 , 95 % CI : 0.49 to 2.91 ; p = 0.70 ) or death ( HR : 1.09 , 95 % CI : 0.57 to 2.07 ; p = 0.79 ) during follow-up was not significantly increased with vorapaxar in patients who had a new ischemic stroke ( n = 204 ) .